No phaseRecruiting
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Biologically-Adapted, Dose-Escalated Accelerated Radiotherapy for Ewing Sarcoma (BEAR)
- Sponsor
- Mayo Clinic (Academic or other)
- Enrolment
- 170 planned
- Conditions
- Ewing Sarcoma; Round Cell Sarcoma With EWSR1-non-ETS Fusion
- Interventions
- Biospecimen Collection; Chemotherapy; Computed Tomography; Conventional Radiotherapy; Definitive Surgical Resection; Dose-escalated Radiation Therapy; Electronic Health Record Review; External Beam Radiation Therapy; Hypofractionated Radiation Therapy; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration
- Ages
- children, adults, older adults
- Registry
- NCT07188532
From the registry
This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy uses minimal imaging support to determine the positioning of radiotherapy. Hypofractionated radiotherapy delivers higher doses of radiotherapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Dose-escalated radiotherapy uses doses that are higher than those used in conventional radiotherapy. Larger tumor sizes and other tumor-specific characteristics have been shown to be related to poorer outcomes. In addition, after dose-escalated radiotherapy, patients with larger tumors have demonstrated improved control of the disease at the primary tumor site. Giving biologically-adapted, dose-escalated radiotherapy may reduce the return of the cancer at the primary tumor site in patients with Ewing sarcoma with large tumors and other…
Primary outcomes
- Reduction in local failure for patients with large tumors (Cohort A)